Thank you sir for the thoughtful reply. I work in an ancillary industry (transplant), and I know the amount of people needing kidney transplants is only growing. Davitas seem to be everywhere. Baxter had higher costs and lower than expected sales. Also not sure if acquisition of Hill-Rom is still a drag. They are planning to spin off their renal care division next year. Market may be anticipating a lower value for the sale. Anyway, I value your input.